Drug Delivery Devices & Primary Pharmaceutical Packaging
Phillips-Medisize provides innovative solutions for complex drug delivery devices and primary pharmaceutical packaging. We have expertise in product design&development, in-house tool making, moulding, welding, assembly, packaging and sterilisation.
Drug Delivery Devices & Primary Pharmaceutical Packaging
Phillips-Medisize offers innovative manufacturing solutions for specialized healthcare products, including complex drug delivery devices as well as primary pharmaceutical packaging such as bottles, closures, dosing systems and flexible containers. Our strength is founded on a deep engineering expertise, supported by advanced manufacturing capabilities like high-speed automated assembly. An own product and design development department is capable to deliver the complete solution - from design to commercialization - for a fully assembled and packaged drug delivery device or primary pharmaceutical packaging.We develop bottles, dosing systems and closures to our customers’ designs and requirements. We can tailor a complete primary packaging system to your needs. Customised drug delivery devices developed and/or produced by us to customer specifications include injector pens, inhalers, syringes with safety devices, inserters and applicators.
Company name: Phillips-Medisize
Website: www.phillipsmedisize.com
E-mail:
eu_sales@phillipsmedisize.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
